$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd

$irwd Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000155837024007640 Filed on May 09, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$94.40M	$74.88M
YoY Change	-12.09%	-28.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$36.96M	$37.61M
YoY Change	-29.57%	20.85%
% of Gross Profit
Research & Development	$30.39M	$25.82M
YoY Change	-12.11%	100.94%
% of Gross Profit
Depreciation & Amortization	$506.0K	$513.0K
YoY Change	87.41%	79.37%
% of Gross Profit
Operating Expenses	$67.35M	$63.42M
YoY Change	-22.64%	44.25%
Operating Profit	$24.98M	$11.02M
YoY Change	-102.31%	-81.66%
Interest Expense	-$6.101M	$7.231M
YoY Change	-431.58%	373.54%
% of Operating Profit	-24.43%	65.62%
Other Income/Expense, Net	-$6.101M	-$6.062M
YoY Change	-188.2%	-205.17%
Pretax Income	$18.88M	$4.958M
YoY Change	-101.75%	-92.47%
Income Tax	$19.70M	$9.100M
% Of Pretax Income	104.37%	183.54%
Net Earnings	-$860.0K	-$4.162M
YoY Change	-99.92%	-109.1%
Net Earnings / Revenue	-0.91%	-5.56%
Basic Earnings Per Share	-$0.01	-$0.03
Diluted Earnings Per Share	-$0.01	-$0.03
COMMON SHARES
Basic Shares Outstanding	159.0M	156.5M
Diluted Shares Outstanding	159.0M	157.7M

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$105.5M	$121.5M
YoY Change	-39.81%	-83.58%
Cash & Equivalents	$105.5M	$121.5M
Short-Term Investments
Other Short-Term Assets	$14.55M	$14.62M
YoY Change	-37.53%	42.17%
Inventory
Prepaid Expenses
Receivables	$58.11M	$72.02M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$178.2M	$208.2M
YoY Change	-43.9%	-75.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.068M	$5.288M
YoY Change	-13.75%	-12.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.257M	$3.398M
YoY Change	8.6%	314.39%
Total Long-Term Assets	$217.4M	$230.6M
YoY Change	-23.87%	-20.17%
TOTAL ASSETS
Total Short-Term Assets	$178.2M	$208.2M
Total Long-Term Assets	$217.4M	$230.6M
Total Assets	$395.6M	$438.8M
YoY Change	-34.42%	-62.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.227M	$6.222M
YoY Change	-7.93%	5172.88%
Accrued Expenses	$41.35M	$44.52M
YoY Change	-57.0%	87.65%
Deferred Revenue	$2.100M	$1.700M
YoY Change	40.0%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$199.8M
YoY Change	-100.0%
Total Short-Term Liabilities	$45.51M	$252.4M
YoY Change	-85.1%	958.77%
LONG-TERM LIABILITIES
Long-Term Debt	$623.6M	$473.5M
YoY Change	4.29%	19.37%
Other Long-Term Liabilities	$34.74M	$29.41M
YoY Change	11.93%	148.77%
Total Long-Term Liabilities	$34.74M	$29.41M
YoY Change	11.93%	148.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$45.51M	$252.4M
Total Long-Term Liabilities	$34.74M	$29.41M
Total Liabilities	$80.25M	$281.9M
YoY Change	-76.15%	690.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.704B	-$1.703B
YoY Change	-0.54%	161.7%
Common Stock	$1.382B	$1.373B
YoY Change	1.11%	1.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$321.7M	-$330.5M
YoY Change
Total Liabilities & Shareholders Equity	$395.6M	$438.8M
YoY Change	-34.42%	-62.02%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$860.0K	-$4.162M
YoY Change	-99.92%	-109.1%
Depreciation, Depletion And Amortization	$506.0K	$513.0K
YoY Change	87.41%	79.37%
Cash From Operating Activities	$33.47M	$44.99M
YoY Change	-4.28%	-43.89%
INVESTING ACTIVITIES
Capital Expenditures	$58.00K	$68.00K
YoY Change	-99.99%	423.08%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$58.00K	-$68.00K
YoY Change	-99.99%	423.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-49.37M	-15.56M
YoY Change	-112.37%	-490.73%
NET CHANGE
Cash From Operating Activities	33.47M	44.99M
Cash From Investing Activities	-58.00K	-68.00K
Cash From Financing Activities	-49.37M	-15.56M
Net Change In Cash	-15.97M	29.39M
YoY Change	-97.18%	-65.07%
FREE CASH FLOW
Cash From Operating Activities	$33.47M	$44.99M
Capital Expenditures	$58.00K	$68.00K
Free Cash Flow	$33.41M	$44.92M
YoY Change	-103.46%	-43.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	158957123
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.ironwoodpharma.com/20240331#CollaborativeArrangementsMember
CY2024Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.ironwoodpharma.com/20240331#CollaborativeArrangementsMember
CY2023Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.ironwoodpharma.com/20240331#CollaborativeArrangementsMember
CY2024Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.ironwoodpharma.com/20240331#CollaborativeArrangementsMember
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001446847
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-34620
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	IRONWOOD PHARMACEUTICALS, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3404176
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	100 Summer Street
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2300
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02110
CY2024Q1	dei	City Area Code CityAreaCode	617
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	621-7722
CY2024Q1	dei	Security12b Title Security12bTitle	Class A common stock, $0.001 par value
CY2024Q1	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.001
CY2024Q1	dei	Trading Symbol TradingSymbol	IRWD
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121540000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	92154000
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	72015000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	129122000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	14619000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	12012000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	208174000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	233288000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5288000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5585000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12208000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	12586000
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3478000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3682000
CY2024Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	206273000
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	212324000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3398000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3608000
CY2024Q1	us-gaap	Assets Assets	438819000
CY2023Q4	us-gaap	Assets Assets	471073000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6222000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7830000
CY2024Q1	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	11880000
CY2023Q4	irwd	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	21331000
CY2024Q1	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	31398000
CY2023Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	44254000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3142000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3126000
CY2024Q1	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	199800000
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	199560000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	252442000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	276101000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14004000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14543000
CY2024Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	198477000
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	198309000
CY2024Q1	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	275000000
CY2023Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	300000000
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	29414000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28415000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	75000000
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	158957123
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	158957123
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	156354238
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	156354238
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	159000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	156000
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1373022000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1355195000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1702777000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1698615000
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-922000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3031000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-330518000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-346295000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	438819000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	471073000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	74877000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104061000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	74877000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104061000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25815000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12847000
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37605000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31117000
CY2024Q1	irwd	Restructuring Expense Benefit RestructuringExpenseBenefit	437000
CY2024Q1	us-gaap	Costs And Expenses CostsAndExpenses	63857000
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	43964000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	11020000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	60097000
CY2024Q1	us-gaap	Interest Expense InterestExpense	7231000
CY2023Q1	us-gaap	Interest Expense InterestExpense	1527000
CY2024Q1	us-gaap	Investment Income Net InvestmentIncomeNet	1169000
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	7272000
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	19000
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6062000
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5764000
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	4958000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	65861000
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9120000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20147000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4162000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	45714000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	157700000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	154452000
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	157700000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	186680000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4162000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	45714000
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1937000
CY2024Q1	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	-172000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2109000
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2053000
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	45714000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-346295000
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	10061000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8385000
CY2024Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	616000
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-4162000
CY2024Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2109000
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-330518000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	652378000
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1629000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7131000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	45714000
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	706852000
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-4162000
CY2023Q1	us-gaap	Profit Loss ProfitLoss	45714000
CY2024Q1	us-gaap	Depreciation Depreciation	513000
CY2023Q1	us-gaap	Depreciation Depreciation	286000
CY2024Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-33000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8385000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7131000
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19000
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	589000
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	402000
CY2024Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	6050000
CY2023Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	17052000
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-57107000
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14298000
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2607000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3669000
CY2024Q1	irwd	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-378000
CY2023Q1	irwd	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-349000
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-30000
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-27000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-12526000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	705000
CY2024Q1	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-9451000
CY2023Q1	irwd	Increase Decrease In Accrued Research And Development Expense IncreaseDecreaseInAccruedResearchAndDevelopmentExpense	-2384000
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-523000
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-479000
CY2024Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1169000
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	758000
CY2024Q1	irwd	Accounts Receivable Net Of Accounts Payable Current And Noncurrent AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent	70900000
CY2023Q4	irwd	Accounts Receivable Net Of Accounts Payable Current And Noncurrent AccountsReceivableNetOfAccountsPayableCurrentAndNoncurrent	112600000
CY2024Q1	irwd	Earnings Per Share Basic Excluding Collaborative Arrangements Revenue Reduction EarningsPerShareBasicExcludingCollaborativeArrangementsRevenueReduction	0.14
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	44985000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	80171000
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	68000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-68000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13000
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	10061000
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3981000
CY2024Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	616000
CY2024Q1	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	25000000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-15555000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3981000
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	29386000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	84139000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92154000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	657938000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	121540000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	742077000
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121540000
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	740342000
CY2023Q1	us-gaap	Restricted Cash RestrictedCash	1735000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	121540000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	742077000
CY2024Q1	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">1. Nature of Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Ironwood Pharmaceuticals, Inc. (“Ironwood” or the “Company”) is a gastrointestinal (“GI”) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. The Company is focused on the development and commercialization of innovative GI product opportunities in areas of significant unmet need, leveraging its demonstrated expertise and capabilities in GI diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">LINZESS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (linaclotide), the Company’s commercial product, is the first product approved by the United States Food and Drug Administration (the “U.S. FDA”) in a class of GI medicines called guanylate cyclase type C agonists (“GC-C agonists”) and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”) and for pediatric patients ages 6-17 years-old suffering from functional constipation (“FC”). LINZESS is available to adult men and women suffering from IBS-C or CIC in the United States (the “U.S.”), Mexico and Saudi Arabia, adult men and women suffering from IBS-C or chronic constipation in Japan, and IBS-C in China, and pediatric patients ages 6-17 years old with FC in the U.S. Linaclotide is available under the trademarked name CONSTELLA<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has strategic partnerships with leading pharmaceutical companies to support the development and commercialization of linaclotide throughout the world. The Company and its partner, AbbVie Inc. (together with its affiliates, “AbbVie”), began commercializing LINZESS in the U.S. in December 2012. Under the Company’s collaboration for North America with <span style="color:#212529;background:#ffffff;">AbbVie</span>, total net sales of LINZESS in the U.S., as recorded by <span style="color:#212529;background:#ffffff;">AbbVie</span>, are reduced by commercial costs incurred by each party, and the resulting amount is shared equally between the Company and <span style="color:#212529;background:#ffffff;">AbbVie</span>. Additionally, development costs are shared equally between the Company and AbbVie.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Outside of the U.S., the Company earns royalties as a percentage of net sales of products containing linaclotide as an active ingredient by the Company’s collaboration partners. AbbVie has an exclusive license from the Company to develop and commercialize linaclotide in all countries other than China (including Hong Kong and Macau), Japan and the countries and territories of North America (the “<span style="color:#212529;background:#ffffff;">AbbVie</span> License Territory”). In addition, <span style="color:#212529;background:#ffffff;">AbbVie</span> has exclusive rights to commercialize linaclotide in Canada as CONSTELLA and in Mexico as LINZESS. Astellas Pharma Inc. (“Astellas”), the Company’s partner in Japan, has an exclusive license to develop, manufacture, and commercialize linaclotide in Japan. AstraZeneca AB (together with its affiliates) (“AstraZeneca”), the Company’s partner in China, has the exclusive right to develop, manufacture, and commercialize products containing linaclotide in China (including Hong Kong and Macau) (the “AstraZeneca License Territory”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In June 2023, the Company completed a tender offer to purchase 98% of the outstanding ordinary shares of VectivBio Holding AG (“VectivBio”), a clinical-stage biotechnology company focused on the discovery and development of treatments for severe, rare GI conditions for which there is a significant unmet medical need (the “VectivBio Acquisition”). In December 2023, the Company completed a squeeze-out merger under Swiss law to acquire all remaining outstanding ordinary shares and VectivBio Holding AG was merged with and into Ironwood Pharmaceuticals GmbH, a wholly-owned subsidiary of Ironwood organized under the laws of Switzerland. Through the acquisition, the Company is advancing apraglutide, a next-generation, synthetic peptide analog of glucagon-like peptide-2, for rare GI diseases, including short bowel syndrome with intestinal failure (“SBS-IF”), a severe malabsorptive condition. In February 2024, the Company announced positive topline results from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in reducing parenteral support dependency in adult patients with SBS-IF, and plans to submit a new drug application and other regulatory filings for apraglutide for use in adult patients with SBS who are dependent on parenteral support. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has a collaboration and license option agreement (the “COUR Collaboration Agreement”) with COUR Pharmaceutical Development Company, Inc. (“COUR”), a biotechnology company developing novel immune-modifying nanoparticles to treat autoimmune diseases. The COUR Collaboration Agreement grants the Company an </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">option to acquire an exclusive license to research, develop, manufacture and commercialize, in the U.S., products containing CNP-104, a potential treatment for primary biliary cholangitis, a rare autoimmune disease targeting the liver.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">These and other agreements are more fully described in Note 4, <i style="font-style:italic;">Collaboration, License and Other Agreements</i>, to these condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is also advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis / bladder pain syndrome and endometriosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company was incorporated in Delaware on January 5, 1998 as Microbia, Inc. On April 7, 2008, the Company changed its name to Ironwood Pharmaceuticals, Inc. To date, the Company has dedicated a majority of its activities to the research, development and commercialization of linaclotide, as well as to the research and development of its other product candidates.</p>
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles requires the Company’s management to make estimates and judgments that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. On an ongoing basis, the Company’s management evaluates its estimates, judgments and methodologies. Estimates and assumptions in the condensed consolidated financial statements include those related to revenue recognition; accounts receivable; useful lives of long-lived assets; impairment of long-lived assets, including goodwill; valuation procedures for right-of-use assets and operating lease liabilities; income taxes, including uncertain tax positions and the valuation allowance for deferred tax assets; research and development expenses; contingencies; defined benefit pension liabilities; and share-based compensation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. </p>
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	129100000
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4162000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	45714000
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4162000
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	46829000
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	157700000
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	154452000
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	157700000
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	186680000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.25
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3934000
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14010000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	74877000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	104061000
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	72000000.0
CY2024Q1	irwd	Earnings Per Share Diluted Excluding Collaborative Arrangements Revenue Reduction EarningsPerShareDilutedExcludingCollaborativeArrangementsRevenueReduction	0.12
CY2022Q1	irwd	Collaborative Arrangement Upfront Payment Received CollaborativeArrangementUpfrontPaymentReceived	3000000000
CY2022Q1	irwd	Collaborative Arrangement Upfront Payment Received CollaborativeArrangementUpfrontPaymentReceived	24600000
CY2022Q1	irwd	Collaborative Arrangement Development Related Payment Received CollaborativeArrangementDevelopmentRelatedPaymentReceived	1100000000
CY2022Q1	irwd	Collaborative Arrangement Development Related Payment Received CollaborativeArrangementDevelopmentRelatedPaymentReceived	9000000.0
CY2022Q1	irwd	Collaborative Arrangement Development Milestones Received CollaborativeArrangementDevelopmentMilestonesReceived	500000000
CY2022Q1	irwd	Collaborative Arrangement Development Milestones Received CollaborativeArrangementDevelopmentMilestonesReceived	4100000
CY2023Q1	irwd	Threshold Percentage Of Collateralized Value ThresholdPercentageOfCollateralizedValue	1.02
CY2023Q1	irwd	Threshold Percentage Of Collateralized Value ThresholdPercentageOfCollateralizedValue	1.02
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	627000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	627000
CY2024Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	384000
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	271000
CY2024Q1	us-gaap	Lease Cost LeaseCost	1011000
CY2023Q1	us-gaap	Lease Cost LeaseCost	898000
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	773000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	757000
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y2M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2354000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3189000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3252000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3318000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3384000
CY2024Q1	irwd	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	4901000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20398000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3252000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	17146000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3142000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14004000
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	398277000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	397869000
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9100000
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12298000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19937000
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	6424000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	5953000
CY2024Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	2961000
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	8303000
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1900000
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1244000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7815000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8817000
CY2024Q1	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	31398000
CY2023Q4	irwd	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	44254000
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7800000
CY2024Q1	irwd	Other Accrued Liabilities Current Uninvoiced Vendor Liabilities OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities	6000000.0
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1700000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8800000
CY2023Q4	irwd	Other Accrued Liabilities Current Uninvoiced Vendor Liabilities OtherAccruedLiabilitiesCurrentUninvoicedVendorLiabilities	6100000
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2600000
CY2019Q3	us-gaap	Payments For Hedge Financing Activities PaymentsForHedgeFinancingActivities	25200000
CY2024Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1723000
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2131000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	203750000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	3000000
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	201500000
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	408250000
CY2024Q1	irwd	Long Term Debt Maturities Interest Payments LongTermDebtMaturitiesInterestPayments	8250000
CY2024Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1723000
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	398277000
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8385000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7131000
CY2024Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1365000
CY2023Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	297000
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	7020000
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	6834000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	20100000

Files In Submission

Name	View Source	Status
0001558370-24-007640-index-headers.html	Edgar Link	pending
0001558370-24-007640-index.html	Edgar Link	pending
0001558370-24-007640.txt	Edgar Link	pending
0001558370-24-007640-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
irwd-20240331.xsd	Edgar Link	pending
irwd-20240331x10q.htm	Edgar Link	pending
irwd-20240331xex31d1.htm	Edgar Link	pending
irwd-20240331xex31d2.htm	Edgar Link	pending
irwd-20240331xex32d1.htm	Edgar Link	pending
irwd-20240331xex32d2.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
irwd-20240331_cal.xml	Edgar Link	unprocessable
irwd-20240331_def.xml	Edgar Link	unprocessable
irwd-20240331_lab.xml	Edgar Link	unprocessable
irwd-20240331_pre.xml	Edgar Link	unprocessable
irwd-20240331x10q_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd

2024 Q2 Form 10-Q Financial Statement

#000155837024007640 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD IRONWOOD PHARMACEUTICALS INC Stock $irwd

2024 Q2 Form 10-Q Financial Statement

#000155837024007640 Filed on May 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IRWD
IRONWOOD PHARMACEUTICALS INC Stock $irwd